A Conversation With FDA Interventional Cardiology Reviewer Andrew Farb
This article was originally published in The Gray Sheet
Executive Summary
When FDA needed experts to guide its response to the emerging drug-eluting stent thrombosis issue in 2006, it was lucky to find it already had a cardiovascular pathologist experienced with implantable devices on its review staff
You may also be interested in...
Upcoming FDA Guidance Will Offer New Thinking On Drug-Eluting Stents
FDA plans to issue a guidance document on drug-eluting stents in the next several months to communicate new premarket and postmarket recommendations for the heavily scrutinized products
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.